Monaco Asset Management SAM Raises Stock Position in Gossamer Bio, Inc. (NASDAQ:GOSS)

Monaco Asset Management SAM lifted its position in shares of Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) by 39.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,371,641 shares of the company's stock after purchasing an additional 1,520,721 shares during the period. Gossamer Bio accounts for approximately 0.7% of Monaco Asset Management SAM's portfolio, making the stock its 14th largest position. Monaco Asset Management SAM owned 2.37% of Gossamer Bio worth $4,859,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of GOSS. Jacobs Levy Equity Management Inc. boosted its holdings in shares of Gossamer Bio by 30.7% during the third quarter. Jacobs Levy Equity Management Inc. now owns 1,887,512 shares of the company's stock worth $1,862,000 after purchasing an additional 442,895 shares during the period. The Manufacturers Life Insurance Company raised its stake in Gossamer Bio by 24.2% in the third quarter. The Manufacturers Life Insurance Company now owns 385,133 shares of the company's stock worth $380,000 after buying an additional 74,920 shares in the last quarter. GSA Capital Partners LLP bought a new position in Gossamer Bio in the third quarter worth about $67,000. US Bancorp DE bought a new position in Gossamer Bio in the third quarter worth about $39,000. Finally, Charles Schwab Investment Management Inc. raised its stake in Gossamer Bio by 1.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,241,979 shares of the company's stock worth $1,123,000 after buying an additional 13,902 shares in the last quarter. 81.23% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Gossamer Bio Stock Up 2.2 %

Shares of NASDAQ GOSS traded up $0.03 on Tuesday, reaching $1.42. 2,647,532 shares of the company's stock traded hands, compared to its average volume of 1,563,638. The business's 50 day simple moving average is $1.14 and its two-hundred day simple moving average is $0.97. Gossamer Bio, Inc. has a 12 month low of $0.50 and a 12 month high of $1.55. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 3.64. The company has a market cap of $321.78 million, a price-to-earnings ratio of -4.44 and a beta of 1.86.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last posted its quarterly earnings results on Tuesday, March 18th. The company reported ($0.15) EPS for the quarter, meeting analysts' consensus estimates of ($0.15). The firm had revenue of $9.38 million for the quarter, compared to analysts' expectations of $7.02 million. As a group, equities research analysts forecast that Gossamer Bio, Inc. will post -0.28 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. Wedbush reissued an "outperform" rating and issued a $4.00 price target on shares of Gossamer Bio in a research note on Friday. HC Wainwright reissued a "buy" rating and issued a $10.00 price target on shares of Gossamer Bio in a research note on Tuesday. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $9.20.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.